<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher C Glisson, DO, MS, FAAN</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H112826026"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neuromyelitis optica spectrum disorder (NMOSD; previously known as Devic disease or neuromyelitis optica [NMO]) is an inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting optic nerves and the spinal cord.</p><p>The epidemiology, pathogenesis, clinical manifestations, and diagnosis of NMOSD will be reviewed here. Treatment and prognosis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H112826032"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>The first clinical descriptions of NMOSD emerged over a century ago when Devic and Gault [<a href="#rid1">1,2</a>] documented a series of patients with a monophasic course of bilateral (or rapidly sequential) optic neuritis and myelitis. Disability following these attacks was often severe. Over time, however, significant variation in the presenting features, clinical course, and the degree of accumulated disability in patients with presumed NMOSD made its distinction from multiple sclerosis less clear [<a href="#rid3">3-8</a>].</p><p>It was previously believed that NMOSD and multiple sclerosis represented one disease entity with variable phenotypes and expression. However, the discovery of a disease-specific serum NMO-immunoglobulin G (IgG) antibody that selectively binds aquaporin-4 (AQP4) has led to increased understanding that NMOSD is distinct from classic relapsing-remitting multiple sclerosis with respect to pathogenesis, imaging features, biomarkers, neuropathology, and treatment.</p><p class="headingAnchor" id="H110399420"><span class="h1">PATHOGENESIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathology</strong> – In NMOSD, florid demyelination and inflammation involve multiple spinal cord segments and the optic nerves with associated astrocyte death, axonal loss, perivascular lymphocytic infiltration, and vascular proliferation [<a href="#rid9">9</a>]. Unlike multiple sclerosis, necrosis and cavitation typically involve both gray and white matter [<a href="#rid7">7</a>]. The neuropathologic features of NMOSD at autopsy are those of a much more severe necrotic lesion of the cord rather than incomplete demyelination. This may be a consequence of the distribution of aquaporin-4 (AQP4) receptors, which predominate in astrocytes rather than oligodendrocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune pathogenesis</strong> - The pathophysiology of NMOSD is thought to be primarily mediated by the humoral immune system [<a href="#rid9">9-12</a>]. Several lines of evidence support an autoimmune pathogenesis for NMOSD. The most important of these was the identification of a NMOSD disease-specific autoantibody, initially termed the NMO-immunoglobulin G (IgG) antibody, and now referred to as the AQP4 autoantibody (see <a class="local">'AQP4 autoantibody'</a> below) [<a href="#rid13">13</a>]. Serum AQP4 autoantibody titers at the nadir of clinical attacks have been shown to correlate with the length of longitudinally extensive spinal cord lesions [<a href="#rid14">14,15</a>]. In addition, serum anti-AQP4 titers have been shown in several studies to correlate with clinical disease activity, drop after immunotherapy, and remain low during remissions, though they are typically not used as an index of therapeutic efficacy during treatment [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Astrocytopathy</strong> – The inflammatory processes in NMOSD primarily target astrocytes, leading to immune-mediated inflammation and secondary demyelination [<a href="#rid17">17-21</a>]. The area postrema appears to be a preferential target of AQP4-IgG antibodies that bind to astrocyte AQP4 water channels, leading to astrocyte dysfunction and the clinical manifestations of nausea and vomiting [<a href="#rid22">22,23</a>]. (See <a class="local">'Brain and brainstem syndromes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AQP4 water channel protein</strong> – AQP4, the target antigen of NMO-IgG, is a water channel protein that is abundant in the astrocytic foot processes at the blood-brain barrier and highly concentrated in spinal cord gray matter, periaqueductal, and periventricular regions [<a href="#rid24">24,25</a>]. AQP4-IgG autoantibodies play a direct role in the pathogenesis of NMOSD [<a href="#rid26">26-28</a>]. In multiple sclerosis (MS) lesions, the distribution of AQP4 protein expression depends upon the stage of demyelination, while in NMOSD lesions, there is a loss of AQP4 expression that is unrelated to the stage of demyelination [<a href="#rid29">29</a>]. In addition, intrathecal anti-AQP4 antibodies have been identified in a patient with NMOSD at disease onset; monoclonal recombinant antibodies generated from this patient induced NMO-specific immunopathology in rats, demonstrating a direct pathogenic role of AQP4 antibodies [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other evidence of an autoimmune etiology</strong> – Additional data supporting an autoimmune pathogenesis for NMOSD include the following observations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histopathologic examination of NMOSD lesions shows immunoglobulin and complement deposits in a characteristic vasculocentric rim and rosette pattern around hyalinized blood vessels [<a href="#rid11">11,29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMOSD is frequently associated with systemic autoimmune disorders, particularly some that are also thought to be mediated by abnormal antibodies; these include organ-specific disorders such as hypothyroidism, pernicious anemia, ulcerative colitis, myasthenia gravis, and idiopathic thrombocytopenic purpura; and nonorgan-specific disorders such as systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's disease [<a href="#rid26">26,30,31</a>]. In addition, some cases of NMOSD may be associated with neoplasms [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear autoantibodies are common in patients with NMOSD who lack evidence of a systemic disorder. In one cohort of 78 patients with NMOSD, seropositivity for antinuclear antibodies (ANA) and Sjögren's disease A/Sjögren's disease B (SSA/SSB) was found in 53 and 17 percent, respectively [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among Japanese patients, Asian optic-spinal multiple sclerosis, now considered part of the spectrum of NMOSD, is associated with the HLA-DPB1-0501 allele of the major histocompatibility complex [<a href="#rid34">34</a>], while conventional MS is associated with the HLA-DRB1-1501 allele. Anti-AQP4 antibody-positive patients are more likely to bear the HLA-DPB1 allele [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical experience and evidence from randomized trials suggest that therapeutic plasma exchange and immunosuppressive therapies targeted to the production of antibodies are beneficial for treatment and prevention of acute NMOSD attacks. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H112826038"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and incidence</strong> – The prevalence of NMOSD in adults in various studies ranges from 0.37 to 10 per 100,000 [<a href="#rid36">36</a>]. Ethnic, geographic, and sex-based disparities are recognized [<a href="#rid36">36,37</a>]. The reported incidence of AQP4-antibody seropositive NMOSD in females is up to 10 times higher than in males [<a href="#rid36">36,38,39</a>], whereas the female-to-male incidence with multiple sclerosis (MS) is approximately 2:1. (See  <a class="medical medical_review" href="/z/d/html/96016.html" rel="external">"Pathogenesis and epidemiology of multiple sclerosis", section on 'Epidemiology and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age of onset</strong> – The median age of onset for NMOSD is 32 to 41 years, but cases are described in children and older adults [<a href="#rid16">16,40-43</a>]. Comparatively, the median age of onset for MS is 24 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geographic distribution</strong> – NMOSD may be overrepresented in some non-European populations worldwide, including African, East Asian, and Latin American populations, among whom conventional MS is somewhat less common [<a href="#rid16">16,36,44</a>]. In a study that determined anti-aquaporin-4 (AQP4)-immunoglobulin G (IgG) seroprevalence, the incidence and prevalence of NMOSD and AQP4 autoimmunity were substantially higher among Black compared with White patients who had inflammatory demyelinating central nervous system disease [<a href="#rid45">45</a>]. As an example, the study found that overall prevalence of NMOSD in the Caribbean island of Martinique (predominantly Black participants) compared with Olmsted County, Minnesota (predominantly White participants) was 10/100,000 versus 3.9/100,000, respectively. However, the ethnic predilection of NMOSD was not supported by some earlier studies [<a href="#rid46">46,47</a>], suggesting it could represent the relative rarity of MS among these groups rather than a true excess of NMOSD [<a href="#rid48">48</a>]. One retrospective report of patients from six centers (Denmark, Germany, South Korea, the United Kingdom, the United States, and Thailand) who were seropositive for AQP4 antibodies found that Asian patients and Black patients had a younger mean age of onset and a higher prevalence of brain and brainstem involvement compared with White patients from these countries [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">In Japan, optic-spinal multiple sclerosis (OSMS), clinically and immunologically similar to NMOSD, represents approximately 15 to 40 percent of MS cases and has been historically identified as a separate disorder, though on a spectrum with conventional Western MS [<a href="#rid49">49</a>]. Whether NMOSD and Asian OSMS are the same entity remains uncertain [<a href="#rid49">49,50</a>]. Nevertheless, Asian OSMS is now considered as part of the NMOSD. (See <a class="local">'Other symptoms'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – NMOSD is usually sporadic, though a few familial cases have been reported [<a href="#rid48">48</a>]. Limited data suggest that genetic variants in the major histocompatibility region are associated with NMOSD [<a href="#rid51">51</a>]. Patients with autoimmune conditions including systemic lupus erythematosus, Sjögren's disease, and myasthenia gravis may have an increased risk for developing NMOSD [<a href="#rid52">52,53</a>].</p><p></p><p class="headingAnchor" id="H112826044"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H3744432144"><span class="h2">Spectrum of symptoms</span><span class="headingEndMark"> — </span>Hallmark features of NMOSD include acute attacks of bilateral or rapidly sequential optic neuritis (leading to severe visual loss) or transverse myelitis (often causing limb weakness, sensory loss, and bladder dysfunction) with a typically relapsing course [<a href="#rid1">1,2,9,40,41,54</a>]. Attacks most often occur over days, with variable degrees of recovery over weeks to months [<a href="#rid55">55</a>].</p><p>Central nervous system involvement outside of the optic nerves and spinal cord is recognized in patients with NMOSD. Other suggestive symptoms include episodes of intractable nausea, vomiting, hiccups, excessive daytime somnolence or narcolepsy, reversible posterior encephalopathy syndrome (PRES), neuroendocrine disorders, and (in children) seizures [<a href="#rid56">56-61</a>]. While no clinical features are disease-specific, some are highly characteristic [<a href="#rid56">56</a>].</p><p>Over time, the range of NMOSD has expanded to include patients with aquaporin-4 (AQP4) antibody positivity who have single or recurrent attacks of optic neuritis, myelitis, or brain or brainstem syndromes, often indistinguishable from multiple sclerosis (MS) [<a href="#rid41">41,56,62-65</a>].</p><p class="headingAnchor" id="H203471859"><span class="h2">Optic neuritis</span><span class="headingEndMark"> — </span>Optic neuritis is reviewed here briefly and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">"Optic neuritis: Prognosis and treatment"</a>.)</p><p>Optic neuritis (inflammation of the optic nerve) can be caused by any inflammatory condition or may be idiopathic. Optic neuritis presents with varying degrees of vision loss is almost always associated with eye pain that worsens with movement of the eye.</p><p>Individual optic neuritis attacks in NMOSD may be similar to isolated syndromes of optic neuritis or those related to MS, though visual loss is generally more severe in NMOSD [<a href="#rid8">8,16,44,54,66</a>]. Involvement of the optic chiasm and tracts is characteristic of NMOSD. While most optic neuritis attacks in NMOSD are unilateral, sequential optic neuritis in rapid succession or bilateral simultaneous optic neuritis is highly suggestive of NMOSD [<a href="#rid16">16</a>]. Papilledema may suggest a diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Optic neuritis'</a>.)</p><p class="headingAnchor" id="H203471948"><span class="h2">Transverse myelitis</span><span class="headingEndMark"> — </span>Transverse myelitis is defined as spinal cord dysfunction developing over hours or days in the absence of a structural spinal cord lesion. Transverse myelitis is reviewed here briefly and discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/14088.html" rel="external">"Transverse myelitis: Etiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manifestations</strong> – Spinal cord involvement in NMOSD typically presents with transverse myelitis, characterized by symmetric paraparesis or quadriparesis, bladder dysfunction, and sensory loss below the level of the spinal cord lesion [<a href="#rid16">16,54</a>]. Accompanying symptoms may include paroxysmal tonic spasms of the trunk or extremities, radicular pain, or Lhermitte sign [<a href="#rid54">54,68</a>]. By contrast, myelitis in MS tends to be incomplete and asymmetric.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Longitudinally extensive transverse myelitis</strong> – Patients with NMOSD typically have a longer extent of spinal cord demyelination than patients with MS [<a href="#rid40">40,54</a>], generally involving three or more vertebral segments on magnetic resonance imaging (MRI), a condition termed longitudinally extensive transverse myelitis (LETM). LETM represents an inaugural or limited form of NMOSD in a high proportion of patients [<a href="#rid69">69</a>]. However, a minority of patients with NMOSD present with a shorter extent of spinal cord involvement [<a href="#rid63">63</a>]. (See <a class="local">'Other symptoms'</a> below.)</p><p></p><p class="headingAnchor" id="H203471955"><span class="h2">Brain and brainstem syndromes</span><span class="headingEndMark"> — </span>In addition to optic neuritis and transverse myelitis, other manifestations that can develop with NMOSD include encephalopathy, fulminant cerebral demyelination, hypothalamic dysfunction, area postrema syndrome, and PRES [<a href="#rid16">16,23,70,71</a>]. In rare cases, severe diffuse cerebral edema and demyelination can lead to brain herniation and death [<a href="#rid71">71</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Area postrema syndrome</strong> – Some patients with NMOSD present with brainstem symptoms due to medullary involvement. In particular, the area postrema clinical syndrome of nausea and vomiting or hiccups, sometimes intractable, with associated medullary lesions on MRI occurs with an incidence of 16 to 43 percent in NMOSD [<a href="#rid56">56,69,72</a>]. Brainstem involvement may lead to acute neurogenic respiratory failure and death [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothalamic lesions</strong> – Symptoms related to bilateral hypothalamic lesions may include symptomatic narcolepsy or excessive daytime sleepiness, obesity, and various autonomic manifestations such as hypotension, bradycardia, and hypothermia [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyponatremia</strong> – Hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion or to cerebral salt-wasting syndrome has been associated with seropositive AQP4 antibody NMOSD [<a href="#rid73">73,74</a>].</p><p></p><p class="headingAnchor" id="H1376688478"><span class="h2">Other symptoms</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle involvement </strong>– Beyond the central nervous system involvement characteristic of NMOSD, muscle may be a target of attacks in rare cases. There is at least one case report of a patient with NMOSD who had recurrent myalgias and evidence of an autoimmune myopathy with targeting of sarcolemmal AQP4 in skeletal muscle by complement-activating immunoglobulin G [<a href="#rid75">75</a>]. In addition, there are several reports of transiently elevated serum creatine kinase (ie, "hyper-CKemia") associated with attacks of NMOSD [<a href="#rid65">65,76-79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong> – Pain is a common symptom. In retrospective studies of NMOSD, 75 to 80 percent of patients report pain, most often involving the trunk and legs [<a href="#rid80">80-82</a>].</p><p></p><p class="headingAnchor" id="H129959203"><span class="h2">Children</span><span class="headingEndMark"> — </span>Although firm conclusions are limited by small numbers of patients, the available data suggest that a substantial minority of children with NMOSD have brain involvement at presentation associated with clinical features of encephalopathy, seizures, and/or lesions on brain MRI resembling those typically seen with MS or acute disseminated encephalomyelitis [<a href="#rid59">59,83-88</a>].</p><p class="headingAnchor" id="H203471962"><span class="h2">Relapsing clinical course</span><span class="headingEndMark"> — </span>NMOSD has a relapsing course in 90 percent or more of cases [<a href="#rid40">40,42,54</a>]. In some patients, optic neuritis and transverse myelitis occur concurrently; in others, clinical episodes are separated by a variable time delay. Relapse occurs within the first year following an initial event in 60 percent of patients and within three years in 90 percent [<a href="#rid54">54</a>].</p><p>As a rule, severe residual deficits follow initial and subsequent attacks, leading to rapid development of disability due to blindness and paraplegia within five years [<a href="#rid54">54,89,90</a>]. Unlike MS, a secondary progressive phase of the disease is rare, and disability is associated with specific attacks. Patients with cerebral presentations may have continued brain attacks without involvement of the optic nerves or spinal cord [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H203475498"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H3602741198"><span class="h2">When to suspect NMOSD</span><span class="headingEndMark"> — </span>Clinical presentations that should raise suspicion for NMOSD include the following [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Optic neuritis that is simultaneously bilateral, involves the optic chiasm, causes an altitudinal visual field defect, or causes severe residual visual loss</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A complete (rather than partial) spinal cord syndrome, especially with paroxysmal tonic spasms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An area postrema clinical syndrome consisting of intractable hiccups or nausea and vomiting</p><p></p><p>However, none of these presentations are diagnostic for NMOSD when anti-aquaporin-4 (AQP4)-immunoglobulin G (IgG) antibodies are not detected and, conversely, the continuum of NMOSD can be wider, based upon the presence of AQP4-IgG antibodies in milder spinal cord syndromes [<a href="#rid56">56</a>]. In some patients, anti-myelin oligodendrocyte glycoprotein (MOG) antibodies are associated with similar syndromes. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"</a>.)</p><p>Other clinical and imaging manifestations are considered "red flags"  (<a class="graphic graphic_table graphicRef102846" href="/z/d/graphic/102846.html" rel="external">table 1</a>) that raise the likelihood of alternative diagnoses. Of these, a gradual progressive course of neurologic worsening over months or years is very unusual in NMOSD.</p><p class="headingAnchor" id="H3480490006"><span class="h2">Investigations</span><span class="headingEndMark"> — </span>The evaluation of suspected NMOSD entails the following investigations:</p><p class="bulletIndent1"><span class="glyph">●</span>MRI, with and without contrast, of the brain and spinal cord. In some cases, spinal arteriography may be needed to confirm the diagnosis of vascular pathologies that can present as acute myelopathies, such as dural arteriovenous fistula.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum for AQP4-IgG antibody and MOG-IgG antibody testing, using a cell-based assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) analysis is not strictly required for the diagnosis of NMOSD but is used to distinguish from other entities such as multiple sclerosis, since for example oligoclonal bands are not usually present in NMOSD, unlike multiple sclerosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most clinicians also obtain assays for other autoimmune conditions such as systemic lupus erythematosus and Sjögren's disease, as well as antibodies against HIV as part of the workup.</p><p></p><p>The detection of AQP4-IgG antibodies is specific for confirming the diagnosis  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) in appropriate clinical settings.</p><p class="headingAnchor" id="H1324510151"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Revised consensus criteria published in 2015  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) base the diagnosis of NMOSD on the presence of core clinical characteristics, AQP4 antibody status, and MRI neuroimaging features  (<a class="graphic graphic_table graphicRef102843" href="/z/d/graphic/102843.html" rel="external">table 3</a>) [<a href="#rid56">56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Core clinical features of NMOSD</strong> – The criteria recognize six core clinical characteristics, which are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Optic neuritis</p><p class="bulletIndent2"><span class="glyph">•</span>Acute myelitis</p><p class="bulletIndent2"><span class="glyph">•</span>Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Acute brainstem syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions</p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic cerebral syndrome with NMOSD-typical brain lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis with AQP4-IgG </strong>– The diagnosis of NMOSD with AQP4-IgG antibodies  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) requires the following [<a href="#rid56">56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one core clinical characteristic</p><p class="bulletIndent2"><span class="glyph">•</span>A positive test for AQP4-IgG using the best available detection method (cell-based assay strongly recommended)</p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of alternative diagnoses</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis without</strong> <strong>AQP4-IgG </strong>– The diagnostic criteria for NMOSD with negative or unknown AQP4-IgG antibody status are more exacting  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) and require [<a href="#rid56">56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least two core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis, or area postrema syndrome</p><p class="bulletIndent3"><span class="glyph">-</span>Dissemination in space (two or more different core clinical characteristics)</p><p class="bulletIndent3"><span class="glyph">-</span>Fulfillment of additional MRI requirements  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) as determined by the clinical presentation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Negative tests for AQP4-IgG (NMO-IgG) using cell-based methods (this criterion is waived if testing is unavailable)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exclusion of alternative diagnoses</p><p></p><p class="headingAnchor" id="H203475505"><span class="h2">Spinal cord MRI</span><span class="headingEndMark"> — </span>Longitudinally extensive spinal cord lesions on T2-weighted MRI, particularly those extending for three or more vertebral segments and primarily involving the central cord gray matter on axial sections, are highly suggestive of NMOSD  (<a class="graphic graphic_table graphicRef102843" href="/z/d/graphic/102843.html" rel="external">table 3</a> and <a class="graphic graphic_diagnosticimage graphicRef102862" href="/z/d/graphic/102862.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef119495" href="/z/d/graphic/119495.html" rel="external">image 2</a>) [<a href="#rid54">54,92,93</a>]. Acute lesions generally involve most of the cross-sectional area of a spinal segment, with edema and gadolinium enhancement. The "owl-eye" sign is due to hyperintensities of the anterior horn cells in the spinal gray matter, suggesting spinal artery ischemia; it may be seen acutely, and cavitation is present in severe cases [<a href="#rid16">16</a>]. The cervical cord is affected in approximately 60 percent of cases, and lesions may extend into the medulla [<a href="#rid94">94</a>]. Occasionally, the spinal cord inflammation and swelling have been so severe that the lesion can mimic a tumor [<a href="#rid95">95-97</a>]. Gadolinium enhancement disappears with treatment, and spinal cord lesions diminish during remissions [<a href="#rid16">16</a>]. Over time, there may be significant spinal cord atrophy  (<a class="graphic graphic_diagnosticimage graphicRef102862" href="/z/d/graphic/102862.html" rel="external">image 1</a>).</p><p class="headingAnchor" id="H203475518"><span class="h2">MRI of the brain and orbits</span><span class="headingEndMark"> — </span>At presentation, MRI of the brain is normal in 55 to 84 percent of patients with NMOSD, aside from gadolinium enhancement of the optic nerves  (<a class="graphic graphic_table graphicRef102843" href="/z/d/graphic/102843.html" rel="external">table 3</a>) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Magnetic resonance imaging'</a>.).</p><p>Over time, however, MRI evidence of brain involvement develops in up to 85 percent of patients with NMOSD [<a href="#rid98">98-101</a>]. Lesions are described in the central medulla, hypothalamus, and diencephalon, corresponding to regions of high AQP4 expression, but are also found within subcortical white matter  (<a class="graphic graphic_diagnosticimage graphicRef102863" href="/z/d/graphic/102863.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef102864" href="/z/d/graphic/102864.html" rel="external">image 4</a>). These lesions in patients with NMOSD occasionally fulfill MS diagnostic criteria for dissemination in space. Lesions of the corticospinal tract also suggest NMO [<a href="#rid91">91</a>]. Ring-enhancing lesions, either open or closed, are characteristic of MS, not NMO. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'McDonald diagnostic criteria'</a>.)</p><p>Like the longitudinally extensive spinal cord lesions of NMOSD, lesions of the optic nerve tend to be extensive [<a href="#rid102">102</a>]. Inflammation in the optic nerves extends more posteriorly than in MS, often involving the optic chiasm and tracts. In a small retrospective study reporting imaging of optic neuritis with MRI, contrast enhancement of the optic chiasm  (<a class="graphic graphic_diagnosticimage graphicRef119499" href="/z/d/graphic/119499.html" rel="external">image 5</a>) was observed in some patients diagnosed with NMOSD but was not found in patients diagnosed with multiple sclerosis, suggesting it is a reliable differentiator between the two conditions [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H203476707"><span class="h2">AQP4 autoantibody</span><span class="headingEndMark"> — </span>Patients suspected of having NMOSD should be tested for serum AQP4-IgG antibodies [<a href="#rid56">56,65</a>]. Ideally, testing for AQP4 antibody status should be performed during attacks and before immunotherapy, since conversion to seronegative status may occur with immunotherapy [<a href="#rid104">104</a>]. In addition, patients who are initially seronegative for AQP4 antibody should be retested if there is suspicion for NMOSD.</p><p>The original NMO-IgG serum assay demonstrated moderate sensitivity and high specificity for the detection of NMOSD (73 and 91 percent, respectively) in addition to Asian optic-spinal MS (58 and 100 percent, respectively) [<a href="#rid13">13,105</a>]. Further-refined antigen-specific anti-AQP4 antibody assays may be more sensitive than the original NMO-IgG assay. A case-control study found 91 percent sensitivity and 100 percent specificity of anti-AQP4 antibody for NMOSD [<a href="#rid14">14</a>]. A blinded, multicenter trial confirmed a high specificity (100 percent) but only moderate sensitivity (72 percent) using combined commercial cell-based assay and enzyme-linked immunosorbent assay against AQP4 [<a href="#rid106">106</a>].</p><p>The AQP4-IgG serum autoantibody, also known as NMO-IgG based on its original name, is a specific biomarker for NMOSD [<a href="#rid56">56,65</a>]. The AQP4 receptor is the target antigen of NMO-IgG, which has a direct role in the pathogenesis of NMOSD. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Even using the most sensitive cell-based assays, 12 percent of patients with a clinical diagnosis of NMOSD are seronegative for AQP4-IgG [<a href="#rid104">104</a>]. Limited data suggest that seronegative NMOSD may differ from seropositive NMOSD on certain features, including an equal male to female ratio and a greater likelihood of simultaneous optic neuritis and transverse myelitis at first presentation [<a href="#rid104">104,107</a>].</p><p class="headingAnchor" id="H3872086890"><span class="h2">MOG autoantibody</span><span class="headingEndMark"> — </span>A minority of AQP4-seronegative patients with a phenotype of NMOSD has serum antibodies against MOG [<a href="#rid108">108-111</a>]. MOG autoantibodies define an overlapping clinical syndrome known as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) that often meets the clinical criteria for NMOSD but has some differences in features compared with AQP4 antibody-associated NMOSD, as summarized in the table  (<a class="graphic graphic_table graphicRef131849" href="/z/d/graphic/131849.html" rel="external">table 4</a>), including [<a href="#rid109">109,112-116</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>More likely to involve the optic nerve than the spinal cord</p><p class="bulletIndent1"><span class="glyph">●</span>More likely to present with simultaneous bilateral optic neuritis with papilledema on funduscopic examination</p><p class="bulletIndent1"><span class="glyph">●</span>More likely to be monophasic or to have fewer relapses</p><p class="bulletIndent1"><span class="glyph">●</span>Less likely to be associated with other autoimmune disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Proportionally more brainstem and cerebellar lesions, and fewer supratentorial lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Spinal cord lesions mainly occur in the lower portion of the spinal cord</p><p class="bulletIndent1"><span class="glyph">●</span>The spectrum of disease includes acute disseminated encephalomyelitis (ADEM), particularly in children</p><p class="bulletIndent1"><span class="glyph">●</span>The male to female ratio is close to 1:1, unlike the predominance of females in NMOSD with AQP4-IgG antibodies</p><p></p><p>Proposed diagnostic criteria for MOGAD require serum positivity for MOG-IgG by cell-based assay, a clinical presentation consistent with central nervous system demyelination (ie, ADEM, optic neuritis, transverse myelitis, a brain or brainstem demyelinating syndrome, or any combination of these), and exclusion of an alternative diagnosis [<a href="#rid117">117</a>]. In the absence of serum positivity, CSF positivity for MOG-IgG allows fulfillment of the criteria. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p>MOGAD is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/132021.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H129997392"><span class="h2">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>A lumbar puncture is often unnecessary in patients with a typical presentation of NMOSD. However, it may be helpful to distinguish NMOSD from MS when the diagnosis is uncertain. During acute attacks of NMOSD, CSF abnormalities are common, including pleocytosis and elevated protein levels. Pleocytosis is detected in 14 to 79 percent of patients with NMOSD, typically monocytes or lymphocytes, though neutrophils may predominate. A CSF white blood count &gt;50 cells/mm<sup>3</sup> is reported in 13 to 35 percent of patients with NMOSD; those with longitudinally extensive spinal cord lesions show a higher incidence than those with optic neuritis [<a href="#rid16">16,40,54</a>]. Notably, oligoclonal bands are typically absent (70 to 85 percent of cases) [<a href="#rid16">16,40</a>].</p><p>By contrast, a CSF pleocytosis &gt;50 cells/mm<sup>3</sup> is rare in MS, while oligoclonal bands are present in over 90 percent of patients. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'CSF analysis and oligoclonal bands'</a>.)</p><p class="headingAnchor" id="H203476720"><span class="h2">Optical coherence tomography</span><span class="headingEndMark"> — </span>Optical coherence tomography studies in NMOSD report significantly greater retinal nerve fiber layer thinning in patients with NMOSD than MS, reflecting more severe axonal insult [<a href="#rid118">118,119</a>]. Microcystic macular edema of the inner nuclear layer appears to be common among patients with NMOSD and a history of optic neuritis [<a href="#rid120">120</a>]. In patients with NMOSD-related optic neuritis, other studies have reported retinal microvascular changes, as measured by radial peripapillary capillary density and macular superficial vessel density, and reduced thickness of the combined ganglion cell and inner plexiform layer [<a href="#rid121">121,122</a>]. However, the utility of optical coherence tomography as a diagnostic tool is not well established. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Optical coherence tomography'</a>.)</p><p class="headingAnchor" id="H244107949"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The most common considerations in the differential diagnoses of aquaporin-4 (AQP4)-immunoglobulin G (IgG) antibody-positive NMOSD are multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). A comparison of these three disorders is summarized in the table  (<a class="graphic graphic_table graphicRef131849" href="/z/d/graphic/131849.html" rel="external">table 4</a>). MRI discriminating features are illustrated in the figures for orbital and brain MRI  (<a class="graphic graphic_diagnosticimage graphicRef131860" href="/z/d/graphic/131860.html" rel="external">image 6</a>) and for spine MRI  (<a class="graphic graphic_diagnosticimage graphicRef131863" href="/z/d/graphic/131863.html" rel="external">image 7</a>).</p><p>Acute disseminated encephalomyelitis and other autoimmune diseases such as systemic lupus erythematosus and Behçet disease may rarely have similar presentations as NMOSD [<a href="#rid123">123-125</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing MOGAD from NMOSD</strong> – It is relatively easy to distinguish MOGAD from AQP4-IgG NMOSD, as both have reliable serum biomarkers, and dual positivity of MOG-IgG and AQP4-IgG is rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing multiple sclerosis from NMOSD</strong> – Multiple sclerosis is the most common disorder likely to cause central nervous system demyelination. Differentiating NMOSD from other demyelinating disorders is based upon important differences with respect to clinical course, prognosis, and underlying pathophysiology  (<a class="graphic graphic_table graphicRef102846" href="/z/d/graphic/102846.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef131849" href="/z/d/graphic/131849.html" rel="external">table 4</a>) as well as responsiveness to MS disease-modifying therapies [<a href="#rid16">16,93</a>]. Several features appear to distinguish NMOSD from classic relapsing-remitting multiple sclerosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brain MRI is often normal in patients with NMOSD, particularly at onset, and spinal cord MRI typically exhibits extensive lesions spanning three or more vertebral segments. However, clinical or MRI evidence of brain involvement, particularly in the brainstem, occurs in a substantial proportion of patients with NMOSD [<a href="#rid98">98-100</a>]. Of note, ring-enhancing lesions, either open or closed, are typical of MS, not NMO. Additional findings on brain MRI that suggest the diagnosis of MS rather than NMOSD include T2-weighted lesions in one or more of the following locations [<a href="#rid101">101</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lesions adjacent to lateral ventricle</p><p class="bulletIndent3"><span class="glyph">-</span>Inferior temporal lobe white matter lesions</p><p class="bulletIndent3"><span class="glyph">-</span>Ovoid (ie, "Dawson finger") periventricular lesions</p><p class="bulletIndent3"><span class="glyph">-</span>U-fiber juxtacortical lesions</p><p></p><p class="bulletIndent2">However, these neuroimaging findings do not necessarily exclude the diagnosis of NMOSD, as they can occur in patients with NMOSD who are seropositive for AQP4 antibodies [<a href="#rid126">126</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During acute attacks of NMOSD, the cerebrospinal fluid may exhibit a neutrophilic pleocytosis, but it is usually (70 to 85 percent of cases) negative for oligoclonal bands.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The detection of AQP4 antibody positivity is specific for NMOSD. (See <a class="local">'AQP4 autoantibody'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The myelopathy and optic neuritis associated with NMOSD tends to be more severe than with MS, with less likelihood of recovery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential of longitudinally extensive spinal cord lesions</strong> – Longitudinally extensive spinal cord lesions are not specific for NMOSD. They have been described in patients with other autoimmune or inflammatory diseases, including systemic lupus erythematosus, Sjögren's disease, neuro-Behçet disease, sarcoidosis, MS, MOGAD, parainfectious disorders (eg, acute disseminated encephalomyelitis), and anti-N-methyl-D-aspartate receptor encephalitis [<a href="#rid125">125,127,128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myelopathies</strong> – Additional etiologies of acute myelopathy include intrathecal tumors, vascular abnormalities (eg, spinal dural arteriovenous fistula and infarcts due to occlusion of the anterior spinal artery), metabolic conditions (eg, vitamin B12 deficiency causing subacute combined degeneration of the spinal cord), radiation therapy, and viral infections (eg, HIV-1, HTLV-1).</p><p></p><p class="bulletIndent1">Spinal dural arteriovenous malformations should be considered and ruled out as appropriate with either MRI or arteriography.</p><p></p><p class="headingAnchor" id="H3696178911"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H244107942"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord but also the brain and brainstem. NMOSD can be distinguished from multiple sclerosis (MS) and other central nervous system inflammatory disorders by the presence of the disease-specific aquaporin-4 (AQP4) antibody, which plays a direct role in the pathogenesis of NMOSD. (See <a class="local">'History'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The incidence of NMOSD in females is up to 10 times higher than in males. The median age of onset is 32 to 41 years, but there are cases in children and older adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Hallmark features of NMOSD include acute attacks characterized by bilateral or rapidly sequential optic neuritis (leading to visual loss), acute transverse myelitis (often causing limb weakness and bladder dysfunction), and the area postrema syndrome (with intractable hiccups or nausea and vomiting). Other suggestive symptoms include episodes of excessive daytime somnolence or narcolepsy, reversible posterior leukoencephalopathy syndrome, neuroendocrine disorders, and (in children) seizures. While no clinical features are disease-specific, some are highly characteristic. NMOSD has a relapsing course in 90 percent or more of cases. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – In addition to a comprehensive history and examination, the evaluation of suspected NMOSD entails brain and spinal cord neuroimaging with MRI  (<a class="graphic graphic_table graphicRef102843" href="/z/d/graphic/102843.html" rel="external">table 3</a>), determination of AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibody status, and often cerebrospinal fluid analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnostic criteria for NMOSD  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>) require the presence of at least one core clinical characteristic (eg, optic neuritis, acute myelitis, area postrema syndrome), a positive test for AQP4-IgG, and exclusion of alternative diagnoses. The diagnostic criteria are more exacting in the setting of negative or unknown AQP4-IgG antibody status  (<a class="graphic graphic_table graphicRef102828" href="/z/d/graphic/102828.html" rel="external">table 2</a>). Red flags (ie, atypical findings) for the diagnosis of NMOSD are summarized in the table  (<a class="graphic graphic_table graphicRef102846" href="/z/d/graphic/102846.html" rel="external">table 1</a>). (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – NMOSD must be distinguished from MS, which is the most common disorder likely to cause central nervous system demyelination, and from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). A comparison of these three disorders is summarized in the table  (<a class="graphic graphic_table graphicRef131849" href="/z/d/graphic/131849.html" rel="external">table 4</a>). MRI discriminating features are illustrated in the figures for orbital and brain MRI  (<a class="graphic graphic_diagnosticimage graphicRef131860" href="/z/d/graphic/131860.html" rel="external">image 6</a>) and for spine MRI  (<a class="graphic graphic_diagnosticimage graphicRef131863" href="/z/d/graphic/131863.html" rel="external">image 7</a>).</p><p></p><p class="bulletIndent1">Other conditions that should be considered in the differential diagnosis include systemic lupus erythematosus, Sjögren's disease, neuro-Behçet disease, acute disseminated encephalomyelitis, intrathecal spinal cord tumors, vascular abnormalities and infarctions, and neurosarcoidosis. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Devic E. Myélite aiguë compliquée de névrite optique. Bull Med (Paris) 1894; 8:1033.</a></li><li class="breakAll">Gault F. De la neuromyélite optique aiguë, Lyon 1894.</li><li><a class="nounderline abstract_t">Goulden C. Optic neuritis and myelitis. Ophthal Rev 1914; 34:193.</a></li><li><a class="nounderline abstract_t">Beck GM. A case of diffuse myelitis associated with optic neuritis. Brain 1927; 50:687.</a></li><li><a class="nounderline abstract_t">STANSBURY FC. Neuromyelitis optica; presentation of five cases, with pathologic study, and review of literature. Arch Ophthal 1949; 42:292; passim.</a></li><li><a class="nounderline abstract_t">SCOTT GI. Neuromyelitis optica. Am J Ophthalmol 1952; 35:755.</a></li><li><a class="nounderline abstract_t">Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34:162.</a></li><li><a class="nounderline abstract_t">O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60:382.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res 2006; 28:348.</a></li><li><a class="nounderline abstract_t">Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125:1450.</a></li><li><a class="nounderline abstract_t">Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63:2363.</a></li><li><a class="nounderline abstract_t">Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106.</a></li><li><a class="nounderline abstract_t">Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235.</a></li><li><a class="nounderline abstract_t">Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131:3072.</a></li><li><a class="nounderline abstract_t">Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17:1019.</a></li><li><a class="nounderline abstract_t">Parratt JD, Prineas JW. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 2010; 16:1156.</a></li><li><a class="nounderline abstract_t">Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109:1245.</a></li><li><a class="nounderline abstract_t">Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75:208.</a></li><li><a class="nounderline abstract_t">Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Continuum (Minneap Minn) 2019; 25:815.</a></li><li><a class="nounderline abstract_t">Takai Y, Misu T, Suzuki H, et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain 2021; 144:2401.</a></li><li><a class="nounderline abstract_t">Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76:1229.</a></li><li><a class="nounderline abstract_t">Magaña SM, Pittock SJ, Lennon VA, et al. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol 2009; 66:964.</a></li><li><a class="nounderline abstract_t">Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473.</a></li><li><a class="nounderline abstract_t">Jung JS, Bhat RV, Preston GM, et al. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A 1994; 91:13052.</a></li><li><a class="nounderline abstract_t">Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66:617.</a></li><li><a class="nounderline abstract_t">Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012; 11:535.</a></li><li><a class="nounderline abstract_t">Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010; 168:1009.</a></li><li><a class="nounderline abstract_t">Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130:1194.</a></li><li><a class="nounderline abstract_t">Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012; 78:1601.</a></li><li><a class="nounderline abstract_t">Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014; 47:154.</a></li><li><a class="nounderline abstract_t">Figueroa M, Guo Y, Tselis A, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol 2014; 71:495.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65:78.</a></li><li><a class="nounderline abstract_t">Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999; 122 ( Pt 9):1689.</a></li><li><a class="nounderline abstract_t">Matsushita T, Matsuoka T, Isobe N, et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009; 73:171.</a></li><li><a class="nounderline abstract_t">Papp V, Magyari M, Aktas O, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology 2021; 96:59.</a></li><li><a class="nounderline abstract_t">Kim SH, Mealy MA, Levy M, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology 2018; 91:e2089.</a></li><li><a class="nounderline abstract_t">Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012; 9:14.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2022; 387:631.</a></li><li><a class="nounderline abstract_t">Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004; 251:47.</a></li><li><a class="nounderline abstract_t">Kim SH, Kim W, Li XF, et al. Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology 2012; 78:1179.</a></li><li><a class="nounderline abstract_t">Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012; 69:1176.</a></li><li><a class="nounderline abstract_t">Maraş H, Kara B, Anık Y. Seropositive neuromyelitis optica: a pediatric case report and 6-year follow-up. Pediatr Neurol 2013; 49:198.</a></li><li><a class="nounderline abstract_t">Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008; 126:12.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016.</a></li><li><a class="nounderline abstract_t">Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009; 256:35.</a></li><li><a class="nounderline abstract_t">Marignier R, De Sèze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 2008; 14:440.</a></li><li><a class="nounderline abstract_t">Matiello M, Kim HJ, Kim W, et al. Familial neuromyelitis optica. Neurology 2010; 75:310.</a></li><li><a class="nounderline abstract_t">Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci 2008; 1142:58.</a></li><li><a class="nounderline abstract_t">Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2:117.</a></li><li><a class="nounderline abstract_t">Estrada K, Whelan CW, Zhao F, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun 2018; 9:1929.</a></li><li><a class="nounderline abstract_t">Shahmohammadi S, Doosti R, Shahmohammadi A, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord 2019; 27:350.</a></li><li><a class="nounderline abstract_t">Jarius S, Paul F, Franciotta D, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 2012; 18:1135.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107.</a></li><li><a class="nounderline abstract_t">Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmun Rev 2014; 13:531.</a></li><li><a class="nounderline abstract_t">Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177.</a></li><li><a class="nounderline abstract_t">Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009; 66:1563.</a></li><li><a class="nounderline abstract_t">Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 2012; 69:1355.</a></li><li><a class="nounderline abstract_t">Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016; 86:245.</a></li><li><a class="nounderline abstract_t">Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72:712.</a></li><li><a class="nounderline abstract_t">Shosha E, Dubey D, Palace J, et al. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 2018; 91:e1642.</a></li><li><a class="nounderline abstract_t">Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80:2210.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72:81.</a></li><li><a class="nounderline abstract_t">Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013; 84:922.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 2016; 1366:20.</a></li><li><a class="nounderline abstract_t">Hokari M, Yokoseki A, Arakawa M, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol 2016; 79:605.</a></li><li><a class="nounderline abstract_t">Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Int J Mol Sci 2020; 22.</a></li><li><a class="nounderline abstract_t">Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69:1026.</a></li><li><a class="nounderline abstract_t">Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010; 68:757.</a></li><li><a class="nounderline abstract_t">Matsushita T, Isobe N, Matsuoka T, et al. Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Mult Scler 2009; 15:1113.</a></li><li><a class="nounderline abstract_t">Newey CR, Bermel RA. Fulminant cerebral demyelination in neuromyelitis optica. Neurology 2011; 77:193.</a></li><li><a class="nounderline abstract_t">Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005; 65:1479.</a></li><li><a class="nounderline abstract_t">Jin S, Long Z, Wang W, Jiang B. Hyponatremia in neuromyelitis optica spectrum disorders: Literature review. Acta Neurol Scand 2018; 138:4.</a></li><li><a class="nounderline abstract_t">Tsagkas C, Schäfer S, Baumgartner A, et al. Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica. Lancet 2021; 397:2194.</a></li><li><a class="nounderline abstract_t">Guo Y, Lennon VA, Popescu BF, et al. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 2014; 71:1025.</a></li><li><a class="nounderline abstract_t">Deguchi S, Deguchi K, Sato K, et al. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 2012; 51:2617.</a></li><li><a class="nounderline abstract_t">Di Filippo M, Franciotta D, Massa R, et al. Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology 2012; 79:1182.</a></li><li><a class="nounderline abstract_t">Yokoyama N, Niino M, Takahashi T, et al. Seroconversion of neuromyelitis optica spectrum disorder with hyperCKemia: a case report. Eur J Neurol 2012; 19:e143.</a></li><li><a class="nounderline abstract_t">Suzuki N, Takahashi T, Aoki M, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010; 74:1543.</a></li><li><a class="nounderline abstract_t">Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011; 77:652.</a></li><li><a class="nounderline abstract_t">Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012; 69:1482.</a></li><li><a class="nounderline abstract_t">Ayzenberg I, Richter D, Henke E, et al. Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol Neuroinflamm 2021; 8.</a></li><li><a class="nounderline abstract_t">McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71:93.</a></li><li><a class="nounderline abstract_t">Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344.</a></li><li><a class="nounderline abstract_t">Lotze TE, Northrop JL, Hutton GJ, et al. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122:e1039.</a></li><li><a class="nounderline abstract_t">Collongues N, Marignier R, Zéphir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75:1084.</a></li><li><a class="nounderline abstract_t">Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol 2012; 27:1437.</a></li><li><a class="nounderline abstract_t">Fragoso YD, Sousa NAC, Saad T, et al. Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. J Child Neurol 2019; 34:487.</a></li><li><a class="nounderline abstract_t">Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114:810.</a></li><li><a class="nounderline abstract_t">Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009; 80:1162.</a></li><li><a class="nounderline abstract_t">Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84:1165.</a></li><li><a class="nounderline abstract_t">Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128.</a></li><li><a class="nounderline abstract_t">Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162.</a></li><li><a class="nounderline abstract_t">Cassinotto C, Deramond H, Olindo S, et al. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol 2009; 36:199.</a></li><li><a class="nounderline abstract_t">Tsivgoulis G, Kontokostas S, Boviatsis E, et al. Teaching neuroimages: neuromyelitis optica misdiagnosed as spinal cord tumor. Neurology 2014; 82:e33.</a></li><li><a class="nounderline abstract_t">Habek M, Adamec I, Brinar VV. Spinal cord tumor versus transverse myelitis. Spine J 2011; 11:1143.</a></li><li><a class="nounderline abstract_t">Brinar M, Rados M, Habek M, Poser CM. Enlargement of the spinal cord: inflammation or neoplasm? Clin Neurol Neurosurg 2006; 108:284.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390.</a></li><li><a class="nounderline abstract_t">Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011; 68:1432.</a></li><li><a class="nounderline abstract_t">Cabrera-Gómez JA, Quevedo-Sotolongo L, González-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler 2007; 13:186.</a></li><li><a class="nounderline abstract_t">Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013; 80:1330.</a></li><li><a class="nounderline abstract_t">Mealy MA, Whetstone A, Orman G, et al. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci 2015; 355:59.</a></li><li><a class="nounderline abstract_t">Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012; 32:216.</a></li><li><a class="nounderline abstract_t">Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197.</a></li><li><a class="nounderline abstract_t">Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68:1076.</a></li><li><a class="nounderline abstract_t">Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78:665.</a></li><li><a class="nounderline abstract_t">Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013; 80:2194.</a></li><li><a class="nounderline abstract_t">Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79:1273.</a></li><li><a class="nounderline abstract_t">Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474.</a></li><li><a class="nounderline abstract_t">Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71:276.</a></li><li><a class="nounderline abstract_t">Wang JJ, Jaunmuktane Z, Mummery C, et al. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology 2016; 87:229.</a></li><li><a class="nounderline abstract_t">Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc 2017; 92:663.</a></li><li><a class="nounderline abstract_t">Weber MS, Derfuss T, Brück W. Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity? JAMA Neurol 2018; 75:909.</a></li><li><a class="nounderline abstract_t">Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018; 25:66.</a></li><li><a class="nounderline abstract_t">de Seze J. MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? Brain 2017; 140:3072.</a></li><li><a class="nounderline abstract_t">Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017; 140:3128.</a></li><li><a class="nounderline abstract_t">López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol 2018; 75:1355.</a></li><li><a class="nounderline abstract_t">Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72:1077.</a></li><li><a class="nounderline abstract_t">Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 2009; 73:302.</a></li><li><a class="nounderline abstract_t">Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 2013; 80:1406.</a></li><li><a class="nounderline abstract_t">Chen Y, Shi C, Zhou L, et al. The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. Front Neurol 2020; 11:35.</a></li><li><a class="nounderline abstract_t">Oertel FC, Specovius S, Zimmermann HG, et al. Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm 2021; 8.</a></li><li><a class="nounderline abstract_t">Graham D, McCarthy A, Kavanagh E, et al. Teaching NeuroImages: longitudinally extensive transverse myelitis in neuro-Behcet disease. Neurology 2013; 80:e189.</a></li><li><a class="nounderline abstract_t">White C, Leonard B, Patel A. Longitudinally extensive transverse myelitis: a catastrophic presentation of a flare-up of systemic lupus erythematosus. CMAJ 2012; 184:E197.</a></li><li><a class="nounderline abstract_t">Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012; 18:271.</a></li><li><a class="nounderline abstract_t">Braksick SA, Cutsforth-Gregory JK, Black DF, et al. Teaching neuroimages: MRI in advanced neuromyelitis optica. Neurology 2014; 82:e101.</a></li><li><a class="nounderline abstract_t">Outteryck O, Baille G, Hodel J, et al. Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol 2013; 13:211.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79:437.</a></li></ol></div><div id="topicVersionRevision">Topic 14089 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myélite aiguëcompliquée de névrite optique</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Myélite aiguëcompliquée de névrite optique</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Optic neuritis and myelitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A case of diffuse myelitis associated with optic neuritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18141060" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neuromyelitis optica; presentation of five cases, with pathologic study, and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14923769" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8338340" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Devic's neuromyelitis optica: a clinicopathological study of 8 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774400" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706564" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The spectrum of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687064" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evidence for humoral autoimmunity in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623701" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Activation of humoral immunity and eosinophils in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589308" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17449477" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18945724" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528913" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EFNS guidelines on diagnosis and management of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823059" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22128336" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644148" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33711152" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368286" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667216" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7528931" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19938104" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608667" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aquaporin 4 and neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699271" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neurological autoimmunity targeting aquaporin-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17282996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551731" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24512514" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733266" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195142" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuromyelitis optica and non organ-specific autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468508" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19140826" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33310876" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30366977" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Racial differences in neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22260418" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36070711" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neuromyelitis Optica Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999489" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459676" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical spectrum of CNS aquaporin-4 autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733096" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23831249" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Seropositive neuromyelitis optica: a pediatric case report and 6-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195212" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical course of optic neuritis in patients with relapsing neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26891082" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224310" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An epidemiological study of neuromyelitis optica in Cuba.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208892" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : NMO-IgG and Devic's neuromyelitis optica: a French experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660861" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Familial neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990121" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neuromyelitis optica and asian phenotype of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849268" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multiple sclerosis in the Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29769526" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476871" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22183934" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496275" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The clinical course of neuromyelitis optica (Devic's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424197" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnosis and classification of neuromyelitis optica (Devic's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092914" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008665" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777080" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26683648" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237699" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30258024" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23677744" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25384099" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23142960" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26096370" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836302" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinicopathological features in anterior visual pathway in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33374173" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473770" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21031587" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intractable vomiting as the initial presentation of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625334" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747076" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Fulminant cerebral demyelination in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275842" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654708" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hyponatremia in neuromyelitis optica spectrum disorders: Literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34090605" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911400" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22989837" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933739" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157245" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Seroconversion of neuromyelitis optica spectrum disorder with hyperCKemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20458072" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Neuromyelitis optica preceded by hyperCKemia episode.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813781" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926050" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association of neuromyelitis optica with severe and intractable pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34108267" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509092" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CNS aquaporin-4 autoimmunity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094334" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838462" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Spectrum of pediatric neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855851" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Long-term follow-up of neuromyelitis optica with a pediatric onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859697" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The spectrum of neuromyelitis optica (NMO) in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31012355" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17141316" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Natural history of the visual impairment of relapsing neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762908" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relapsing neuromyelitis optica: long term history and clinical predictors of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25695963" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : MRI characteristics of neuromyelitis optica spectrum disorder: an international update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156988" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275977" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223076" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24470607" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Teaching neuroimages: neuromyelitis optica misdiagnosed as spinal cord tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082692" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Spinal cord tumor versus transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376015" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Enlargement of the spinal cord: inflammation or neoplasm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533966" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Brain abnormalities in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084126" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Brain involvement in neuromyelitis optica spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17439883" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Brain magnetic resonance imaging findings in relapsing neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23486868" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26026942" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22659839" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23997151" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287449" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : NMO-IgG in the diagnosis of neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302543" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23658379" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914827" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415568" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24425068" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27306633" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385199" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Neuromyelitis Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29913011" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30048919" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29194504" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136091" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Clinical presentation and prognosis in MOG-antibody disease: a UK study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014148" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307541" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636050" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23516321" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : In vivo identification of morphologic retinal abnormalities in neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32117008" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34526385" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Retinal Optical Coherence Tomography in Neuromyelitis Optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23628935" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Teaching NeuroImages: longitudinally extensive transverse myelitis in neuro-Behcet disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083679" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Longitudinally extensive transverse myelitis: a catastrophic presentation of a flare-up of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21669935" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The differential diagnosis of longitudinally extensive transverse myelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24663236" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Teaching neuroimages: MRI in advanced neuromyelitis optica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373538" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Extensive myelitis associated with anti-NMDA receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677112" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Discriminating long myelitis of neuromyelitis optica from sarcoidosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
